Braveheart Investment Group plc
BRH.L
London Stock Exchange2.20
GBp
- -
- -
Braveheart Investment Group plc
BRH.L
(London Stock Exchange)
Recent
price
2.20
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Braveheart Investment Group plc (BRH.L) is a United Kingdom-based investment company that makes strategic principal investments in early and later-stage businesses, primarily in technology, healthcare, biosciences, and knowledge-intensive sectors such as organ-on-a-chip systems, analytical instrumentation, and engineering; it provides debt, equity, mezzanine funding, and advisory services to small- and medium-sized enterprises to build value and facilitate exits, typically holding minority stakes for two to five years with active board involvement where appropriate. The company divides its portfolio into strategic investments including full ownership of Paraytec Limited, which develops high-performance detectors like the portable CX300 flow cytometer for pathogen detection, extracellular vesicle characterization, and next-generation two-colour instruments; 86.11% ownership of Kirkstall Limited, offering the patented Quasi Vivo QV1200 system for organ-on-a-chip research enabling human-relevant toxicology and pharmacokinetics testing without animal models; and stakes in Gyrometric Systems Limited for digital monitoring of rotating machinery in marine and wind energy applications; alongside listed investments such as 29.09% in Autins Group plc for automotive acoustic and thermal insulation solutions, 10.14% in Image Scan Group plc for real-time X-ray screening systems with new AI software, 5.61% in Built Cybernetics plc (formerly Aukett Swanke) for architectural and smart building services following its acquisition of RTS Technology Solutions Limited, and 29.35% in Imaging Biometrics plc for AI-driven neuroimaging and kidney stone analysis software. Founded in 1997 and quoted on the Alternative Investment Market of the London Stock Exchange since 2007, Braveheart maintains its registered office in Glasgow, Scotland, with operational presence historically linked to Barnsley and Perth in the UK and additional offices in Europe and Asia; it targets unquoted emerging companies and undervalued listed entities across manufacturing, food and drink, environmental technologies, financial services, and more, while managing a portfolio of 18 directly held investments valued at £2.27 million as of March 31, 2025. Recent developments include a £1.21 million investment during the year ended March 31, 2025 into Autins Group plc, Image Scan Holdings plc, Imaging Biometrics Limited, and Gyrometric Systems Limited; acquisition of a 29.51% stake in Imaging Biometrics for £719,000 in October 2024 with subsequent participation in a £250,000 placing; Kirkstall's distributor agreements in China with Beijing Kilby Biotechnology and South Korea, alongside enhancements to the QV1200 for organ-on-a-chip applications; Paraytec's UK distribution partnership with Analytik Limited and prototype development of a two-colour CX300 instrument; Gyrometric's leadership in a UK-US Innovate UK-funded project for modular journal bearings in wind turbines with partners including Tufts University and Kingsbury Inc.; a post-period fundraise of £295,000 via placing and broker options; and a sharply reduced pre-tax loss of £1.09 million with net assets of £2.33 million as of March 31, 2025.